DISCLAIMER: This page is intended for members of the general public in Cyprus only.
The information provided on this site is intended for general information and education for Cyprus-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)
NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been granted full approval by the European Commission for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Important information
For more information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601), download the Package Leaflet.
Report an Adverse Event (AE)
If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.
Either you or your healthcare professional can report any suspected adverse reactions via the national reporting system of Cyprus.
Φαρμακευτικές Υπηρεσίες
Υπουργείο Υγείας
CY-1475 Λευκωσία
Τηλ: +357 22608607
Φαξ: + 357 22608669
Ιστότοπος: www.moh.gov.cy/phs
Contact Us
Tel: +357 22 090614
09:00 - 17:00
Monday - Friday